Pzena Investment Management LLC Sells 578,950 Shares of Phibro Animal Health Corporation (NASDAQ:PAHC)

Pzena Investment Management LLC lowered its stake in Phibro Animal Health Corporation (NASDAQ:PAHC - Free Report) by 44.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 723,830 shares of the company's stock after selling 578,950 shares during the quarter. Pzena Investment Management LLC owned approximately 1.79% of Phibro Animal Health worth $15,461,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Man Group plc purchased a new stake in shares of Phibro Animal Health in the fourth quarter valued at $501,000. GAMMA Investing LLC lifted its stake in Phibro Animal Health by 2,011.4% in the 1st quarter. GAMMA Investing LLC now owns 36,718 shares of the company's stock worth $784,000 after acquiring an additional 34,979 shares in the last quarter. Lazard Asset Management LLC boosted its position in Phibro Animal Health by 2,739.7% during the 4th quarter. Lazard Asset Management LLC now owns 1,647 shares of the company's stock worth $34,000 after acquiring an additional 1,589 shares during the period. Nuveen Asset Management LLC boosted its position in Phibro Animal Health by 21.4% during the 4th quarter. Nuveen Asset Management LLC now owns 588,001 shares of the company's stock worth $12,348,000 after acquiring an additional 103,618 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Phibro Animal Health by 37.1% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 62,566 shares of the company's stock valued at $1,314,000 after acquiring an additional 16,917 shares in the last quarter. Institutional investors and hedge funds own 99.34% of the company's stock.

Wall Street Analysts Forecast Growth

PAHC has been the topic of several analyst reports. Morgan Stanley set a $26.00 price target on shares of Phibro Animal Health and gave the stock an "equal weight" rating in a research note on Wednesday, June 25th. JPMorgan Chase & Co. upgraded Phibro Animal Health from a "neutral" rating to an "overweight" rating and upped their price target for the stock from $25.00 to $35.00 in a research note on Monday, July 7th. BNP Paribas Exane raised Phibro Animal Health from an "underperform" rating to a "neutral" rating and set a $24.00 price objective on the stock in a research note on Monday, June 16th. BNP Paribas raised Phibro Animal Health to a "hold" rating in a research report on Monday, June 16th. Finally, Wall Street Zen raised shares of Phibro Animal Health from a "hold" rating to a "buy" rating in a research report on Friday, May 9th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, Phibro Animal Health currently has a consensus rating of "Hold" and an average target price of $24.40.

Phibro Animal Health Trading Down 0.9%

PAHC stock traded down $0.27 during trading on Monday, hitting $29.14. The company had a trading volume of 302,501 shares, compared to its average volume of 225,288. The firm has a 50-day moving average price of $25.87 and a 200-day moving average price of $22.84. Phibro Animal Health Corporation has a 12 month low of $16.16 and a 12 month high of $31.80. The company has a quick ratio of 1.23, a current ratio of 2.91 and a debt-to-equity ratio of 2.67. The stock has a market cap of $1.18 billion, a price-to-earnings ratio of 37.36, a PEG ratio of 0.49 and a beta of 0.75.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.63 EPS for the quarter, topping analysts' consensus estimates of $0.52 by $0.11. The business had revenue of $347.80 million for the quarter, compared to analyst estimates of $352.41 million. Phibro Animal Health had a net margin of 2.68% and a return on equity of 30.51%. As a group, analysts predict that Phibro Animal Health Corporation will post 1.95 earnings per share for the current year.

Phibro Animal Health Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, June 25th. Investors of record on Wednesday, June 4th were issued a dividend of $0.12 per share. The ex-dividend date was Wednesday, June 4th. This represents a $0.48 dividend on an annualized basis and a yield of 1.65%. Phibro Animal Health's payout ratio is 61.54%.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.